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Abstract We report the characterization of a novel human 7- 
glutamyltransferase mRNA type. This type III mRNA differs 
from type I and type II mRNAs previously described by several 
point mutations and the presence of an unspliced 81 bp intron in 
the open reading frame. Further, type III mRNAs are truncated 
ones and are tissue and pathology specifically expressed. In fact, 
type III mRNAs are present in human placenta, sigmoid, lung 
and in 50% of acute lymphoblastic leukemia blood cells but they 
are never found in healthy lymphocytes. 
Key words: ~,-Glutamyltranspeptidase; Multigenic family; 
Truncated mRNA;  Leukemia 
1. Introduction 
y-Glutamyltranspeptidase (EC 2.3.2.2, GGT) is a plasma 
membrane-bound heterodimeric enzyme that catalyses the hy- 
drolysis or transfer of the y-glutamyl moiety from glutathione 
and other ?-glutamyl-containing compounds to an amino acid 
or dipeptide, to water or to glutathione [1,2]. 
Human GGT is a multigenic family composed of at least 
7 loci [3]. Five of them are located on chromosome 22 [4] in 
the bcr region (break point cluster region) which is involved in 
chromosomal breaks and rearrangements a sociated with var- 
ious diseases [5]. 
Human GGT mRNAs expressed in placenta [6], pancreas 
[7], fetal liver [8], lung [9] and HepG2 hepatoma [10] have 
been described previously and show a unique ORF. This 
ORF  encodes for a single polypeptide precursor which upon 
cleavage during the post-translational process gives rise to the 
two non-identical subunits of the mature enzymes (large sub- 
unit 55-60 kDa, small subunit 21-30 kDa) [11]. These 
mRNAs,  named type I mRNA,  seem to be encoded by our 
ubiquitously expressed GGT gene (gene 6) [3]. 
Wetmore et al. [9] have characterized another type I mRNA 
expressed in human lung which is truncated in the sequences 
encoding the large subunit. The sequences encoding the small 
subunit are identical to type I mRNA. 
Another mRNA,  named type II, is encoded by gene 3 and 
expressed in human kidney and has been described by Pawlak 
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et al. [12]. It contains several point mutations in comparison 
to type I mRNA.  Actually, no protein translated from this 
mRNA has been identified. 
It has been reported that at least three more GGT genes are 
expressed in human tissues and cell lines although no further 
characterization of the corresponding transcipts has been at- 
tempted [3]. Among them, gene 1 transcripts eem to be the 
most interesting as they were found in placenta, which pre- 
sents a high GGT activity, in lung and sigmoid. Furthermore, 
GGT activity is known to be modulated in several disorders 
including cancer diseases [13] and also during blood cell dif- 
ferentiation [14]. In acute lymphoblastic leukemia, GGT ac- 
tivities in white blood cells are modified [15]. 
The aim of our studies was first to clone and to characterize 
the GGT type III mRNA.  Furthermore, we studied the ex- 
pression of type I and type III mRNAs in healthy and ALL 
subjects. 
2. Materials and methods 
2.1. Biological samples 
Peripheral blood was collected in EDTA-Vacutainer tubes (Beck- 
ton-Dickinson, USA) according to a protocol approved by the 'Co- 
mit6 de Protection des Personnes'. 
Normal blood was obtained from 10 healthy volunteers between 20 
and 30 years old. 
Lymphocytic fractions were obtained by Ficoll-Paque (Sigma, 
USA) gradient centrifugation [16] from blood of 17 admitted patients 
both male and female (2-15 years old) (department of Prof. D. Som- 
melet at the M6decine Infantile II, H6pital d'Enfants de Brabois, 
Vandoeuvre-16s-Nancy, France) who had a hematologic diagnosis of 
acute lymphocytic leukemia (5 bone narrow relapses, 1 remission and 
11 diagnoses). Total RNA was extracted using the guanidinium thio- 
cyanate method [17]. 
Hematopoietic cell lines HL60, U937 and K562 were subcultured in
RPMI-1640 medium (Gibco-BRL, France) supplemented with 5% fe- 
tal calf serum (Boehringer-Mannheim, France) in a humidified atmos- 
phere of 95% air, 5% CO2 at 37°C. Total RNA was extracted from 
confluent cells as described previously. 
2.2. Reverse transcription 
The conversion of RNA to cDNA was carried out in final volume 
of 50 Jal containing 1-5/.tg of total RNA extracted from the lympho- 
cyte fraction, cultured cells or placenta, 50 mM Tris-HCl, pH 7.6, 70 
mM KCI, 10 mM MgC12, 4 mM dithiothreitol, 10 ng oligo-d(T)12 18 
primer (Gibco-BRL, France), 1 mM each dNTP, 40 U of 'RNA 
guard' (Pharmacia, France) and 200 U of MMLV reverse transcrip- 
tase (Gibco-BRL, France). Before adding RNA guard and reverse 
transcriptase, the mixture was heated at 70°C for 5 rain and the 
reaction was quenched on ice. Reverse transcription was then carried 
out at 37°C for 90 min and stopped by cooling on ice. 
2.3. DNA amplification and cloning 
cDNA was amplified with Taq DNA polymerase (Boehringer- 
Mannheim, Germany) in a thermal cycler (Perkin Elmer-Cetus, 
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USA). Samples were prepared with 5 gl of the cDNA solution in a 
total volume of 100 gl containing the following PCR mixture: 
1 ×PCR buffer (10 mM Tris-HC1, pH 8.3, 50 mM KCI, 1.5 mM 
MgC12, 0.001% gelatine), 250 gM each dNTP and 1 gM of each 5' 
and 3' primer. The mixture was overlaid with mineral oil (Sigma, 
France) and after initial denaturation at 96°C for 6 min, the Taq 
DNA polymerase was added, and then incubated for amplification. 
Steps were: denaturation for 1 rain at 940C, primer annealing for 
1 min at 55°C, and extension for 2 rain at 72°C. GGT type I 
mRNA specific PCR reactions were conducted with primers Amp 1 
(5'-TTACCTACTGAAGTCGAGAGG-3') and Amp 2 (5'-TCGG- 
CTTGGTCTCCAACATCT-3') for 35 cycles. GGT type III specific 
reactions were performed with Amp 1 and Amp 5 (5'-AAAGGGG- 
TGACACATATCAG-3') for 35 cycles. 
Aliquots of final products were separated on a 3% agarose gel (Nu- 
Sieve, FMC, USA), electrophoresed, visualized under UV illumina- 
tion and blotted onto nylon membrane (Hybond N, Amersham, 
USA). 
Rapid amplification of cDNA 3' ends (3' RACE) was performed as 
in the reverse transcription using 5 gg of human total placental RNA 
and R0-dT (5'-CCGAATTCAA d(T)lT-3') as primer. PCR amplifica- 
tions with Amp 1 as 5' primer and R0-dT as 3' primer (denaturation 
for l min at 94°C, annealing for l min at 55°C and extension for 2 min 
at 72°C) were performed under the conditions described above. Final 
products were separated on 1% agarose, UV visualized, purified and 
cloned into Smal digested pSK vector according to standard pro- 
cedures. 
For 5' RACE experiments, 2 gl of human placental cDNA (Clone- 
tech, USA) were first amplified with Anchor (5'-GGTTCGGCCC- 
ACCTCTGAAGGTTCCAGAATGCAT-3') (Clonetech, USA) as 5' 
primer and Amp 5 as 3' primer for 40 cycles (denaturation for 45 s at 
94°C, annealing for 45 s at 55°C and extension for 2 min at 72°C). 5% 
of these amplification products were reamplified using the same con- 
ditions with Anchor as 5' primer and Amp 5 or Amp 8 (5'-GCAGTC- 
TCTAGACCCGGG-3') as specific 3' primer. 
The products were separated on a 1.5% agarose gel, purified and 
cloned into the pCRI| vector (TA cloning kit, Invitrogen, USA). 
Nucleotide sequence determination was performed using Sanger's 
method [18] with the T7 Sequencing kit (Pharmacia) and (c~-32p)-la  
beled dATP (Dupont-Nemours, USA). 
2.4. Oligonucleotide hybridizations 
The positive control for gene 1 hybridization was the gene 1 Bglll 
restriction fragment cloned in pSK and described by Courtay et al. [3]. 
Blots were prehybridized for 2 h at 65°C in 3XSSC, 10xDen- 
hardt's, 50 gg/ml salmon sperm DNA and 0.1% SDS; hybridization 
was overnight at 55°C in the same solution with a type I (mut 6: 5'- 
CCAACGAGTI'TGGGGTACCC-3') or type III (mut 1 : 5'-CTCTC- 
GTCAATGTGCCCGAC-3') mRNA specific (7-32p)-labeled oligonu- 
cleotide. After post-hybridization washing in 3×SSC, 0.1% SDS at 
550C, membranes were used to expose a film at -80°C for different 
times. 
3. Results 
3.1. Type III GGT mRNAs are specifically amplified with 
Amp 1 and Amp 5 primers 
Courtay et al. [3] have partially described the genomic se- 
quence encoding GGT type III mRNA,  and they have shown 
a point mutation at the 5' end (the normal GT 5' donor site is 
replaced by AT) of an 81 bp intronic sequence that should 
result in an unspliced intron. The oligonucleotide Amp 5 hy- 
bridizes at the 5' end of this putative unspliced intron and 
therefore should be specific for type III GGT mRNAs,  Thus, 
Amp 1 and Amp 5 were used as specific primers for RT-PCR 
reactions on placenta nd sigrnoid RNA where the expression 
of this GGT gene has been previously shown [3]. As shown in 
Fig. IA, the amplification products with Amp 1 and Amp 5 
primers were about 210 bp which is in agreement with the 
theoretical ength. Furthermore, these products specifically 
hybridized with the gene 1 (type III) specific oligonucleotide 
(Fig. 1B, lane 2) while no hybridization occurred when the 
gene 6 (type I) specific oligonucleotide was used instead. Thus, 
the RT-PCR reactions with Amp 5 and Amp 1 primers are 
specific for type III GGT mRNA.  
3.2. Partial cloning of GGT type III mRNA 
3' RACE and 5' RACE were used to clone type III GGT 
mRNA.  
3' RACE was performed using Amp 1 as the 5' primer. 
PCR products were cloned in the SmaI digested pSK phage- 
mid, restriction mapped and sequenced. One clone was found 
to contain a 620 bp insert whose sequence was completely 
identical to the genomic DNA [3] and corresponded to the 
exons encoding the small GGT subunit (Fig. 2). As expected, 
A B 
1 2 3 1 2 3 
Fig. 1. Amp 1-Amp 5 amplification of placental cDNA and gene 1 specific hybridization. 5 gg total placental RNA were subjected to RT-PCR 
amplification with Amp l and Amp 5 as primers and hybridized with gene 1 specific oligoprobe. Lanes: 1, a positive control for gene 1 hybri- 
dization; 2, RT-PCR product obtained with placental RNA as template; 3, ~X DNA digested by HaelII. (A) PCR products were separated 
on 1.5% agarose and visualized by UV light. (B) The gel used in (A) was blotted. Hybridization with a gene 1 specific oligonucleotide was per- 
formed at 55°C; washing of the membrane was carried out at 60°C. 
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-35 AGGCCAGCTCTGGGGTCCGGCAGGTGGTCCGCAACATGACCTC 8 
CCTCCTCAGGCCAGCTCTGGGGTCCGGCAGGTGGTCCGCAACATGACCTC 
Amp8 
9 TGAGTTCTTCGCTCGCCAGCTCCGGGCCCAGATCTCTGACGACACCACTC 58 
TGAGTTCTTCGCTCGCCAGCTCCGGGCCCAGATCTCTGACGACACCACTC 
59 ACCCGATCTCCTACTACAAGCCCGAGTTCTACACGCCGGTTGATGGGGGC 
ACCCGATCTCCTACTACAAGCCCGAGTTCTACACGCCGGTTGATGGGGGC 
108 
109 ACTGCTCACCTGTCTGTCGTCGCAGAGGACGGCAGTGCTGTGTCCGCCAC 
ACTGCTCACCTGTCTGTCGTCGCAGAGGACGGCAGTGCTGTGTCCGCCAC 
158 
159 CAGCACCATCAACCTCTACTTTGGCTCCAAGGTCCGCTCCCCGGTCAGCG 208 
CAGCACCATCAACCTCTACTTTGGCTCCAAGGTCCGCTCCCCGGTCAGCG 
AmDI 
209 GGATCCTGTTCAATGATGAAATGGATGAUTTCAGCTCTCCCAACATCACC 258 
GGATCCTGTTCAATGATGAAATGGATGACTTCAGCTCTCCCAACATCACC 
259 AACGAGTTTGGGGTGCCCCCCTCACCTGCCAATTTCATCCAGCCAGGGAA 
AACGAGTTTGGGGTGCCCCCCTCACCTGCCAATTTCATCCAGCCAGGGAA 
308 
309 GCAGCCGCTCTCGTCAATGTGCCCGACGATCATGGTGGGCCAGGACGGCC 
GCAGCCGCTCTCGTCAATGTGCCCGACGATCATGGTGGGCCAGGACGGCC 
358 
359 AGGTCCGGATGGTGGTGGGAGCTGCTGGGGGCACACAGATCACCACAGCC 408 
AGGTCCGGATGGTGGTGGGAGCTGCTGGGGGCACACAGATCACCACAGCC 
AmD5 
409 ACTGCACTGATATGT~TCACCCCTTTTCTCCCTGGCCGTGCCCACCCTGC 458 
ACTGCACTGATATGTGTCACCCCTTTTCTCCCTGGCCGTGCCCACCCTGC 
459 ACAGCCCCCAAGCCATGCTGATCACACTCCCATGCCCCAGGCCATCATCT 508 
ACAGCCCCCAAGCCATGCTGATCACACTCCCATGCCCCAGGCCATCATCT 
Amp2 
509 ACAACCTCTGGTTCGGCTATGACGTGAAGCGGGCCGTGGAGGAGCCCCGG 558 
ACAACCTCTGGTTCGGCTATGACGTGAAGCGGGCCGTGGAGGAGCCCCGG 
559 CTGCACAACCAGCTTCTGCCCAACGTCACGACAGTGGAGAGAAACATTGA 
CTGCACAACCAGCTTC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
608 
609 CCAGGCAGTGACTGCAGCCCTGGAGACCCGGCACCATCACACCCAGATCG 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
658 
659 CGTCCACCTTCATCGCTGTGGTGCAAGCCATCGTCCGCACGGCTGGTGGC 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
708 
709 TGGGCAGCTGCCTCGGACTCCAGGAAAGGCGGGGTGCCGGCTACTGAGTG 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  TGCCGGCTACTGAGTG 
758 
759 CTCTCCAGGAGGACAAGGCTGACAAGCAATCCAGGGACAAGATACTCACC 
CTCTCCAGGAGGACAAGGCTGACAAGCAATCCAGGGACAAGATACTCACC 
808 
809 AGGACCAGGAAGGGGACTCTGGGGGACTGGCTTCCCCTGTGAGCAGCAGA 858 
AGGACCAGGAAGGGGACTCTGGGGGACTGGCTTCCCCTGTGAGCAGCAGA 
859 GCAGCACAATAAATTGAGGCCACTGTGCAGGCTCCAGGTGGCCTCCCTGC 908 
GCAGCACAATAAATTGAGGCCACT . . . . . . . . . . . . . . . . . . . . . . . . . .  
909 C C T G T C ~  958 
Fig. 2. Comparision of gene 1 genomic and RACE products equence. The upper line contains the type III cDNA sequence and the lower line 
contains the sequence of gene 1 [3]. Bold letters are point mutations compared to type I truncated mRNA; bold and italic letters represent 
start and stop codon; oligonucleotides (Amp 1, Amp 2, Amp 5 and Amp 8) used as primers in PCR reactions are underlined; the unspliced 81 
b intron is dotted underlined. 
HI Leh et al./FEBS Letters 394 (1996) 258~62 261 
1 MTSEFFARQLRAQISDDTTHPISYYKPEFYTPVDGGTAHLSVVAEDGSAV 
MTSEFFAAQLRAQISDDTTHPISYYKPEFYTPDDGGTAHLSWAEDGSAV 
50 
51 SATST INLYFGSKVRSPVSGILFNDEMDDFSSPNITNEFGVPpSPANFIQ 
SATST INLYFGSKVRSPVSGILFNNEMDDFSSPS ITNEFGVPPSPANFIQ 
i00 
i01 PGKQPLSSMCPTIMVGQDGQVRMVVGAAGGTQITTATALICVTPFLPGRA 
PGKQPLSSMCPT IMVGQDGQVRMVVGAAGGTQITTATAL  . . . . . . . . . . .  
150 
151 HPAQPPSHADHTPMPQAIIYNLWFGYDVKIZAVEEPRLHNQLLPNVTTVER 
. . . . . . . . . . . . . . . .  A I IYNLWFGYDVKRAVEEPRLHNQLLPNVTTVER 
200 
201 N IDQAVTA] tLETRHHHTQIASTF IAVVQAIVRTAGGWAAASDSRKGGVPA 
N IDQAVTAALETRI ' IHHTQIASTF IAVVQAIVRTAGGWAAASDSRKGGEPA 
250 
251 TECSPGGQG* 
GY* 
Fig. 3. Amino-acid sequence comparision between type I truncated encoded peptide and the gene 1 putative peptide. The amino acid sequences 
are represented in single-letter code. The upper line contains the peptide derived from type III cDNA sequence and the lower line contains the 
sequence of the protein encode by type I truncated mRNA. Bold letters represent point mutations in type III putative peptide. Italic letters rep- 
resent he amino acids encoded by the unspliced intron. The asterisk represents a stop codon. 
this cDNA contains the unspliced 81 bp intronic sequences, 
while all other introns seem to be correctly spliced. 
5' RACE was performed using Amp 5 as 3' specific primer 
to clone the 5' end of gene 1 mRNA from human placenta. 
PCR reaction products were cloned in pCRII vector and in- 
dividual clones were sequenced. Two clones were found to 
contain 340 bp long inserts whose sequence was also identical 
to the genomic sequence (Fig. 2). As the clones did not reach 
the BgllI site present in GGT cDNAs and in the gene se- 
quences, we performed 5' RACE using Amp 8 as specific 
primer in order to identify the 5' end of the type III 
mRNA. Three individual clones were found to contain the 
same 84 bp insert which was perfectly identical to the corre- 
sponding gene 1 genomic sequence (Fig. 2). As compared to 
the truncated group II wt mRNAs described by Wetmore t al. 
[9], type III mRNAs exhibit the sequences corresponding to 
the region named C and the two bases of the 3' end of the 
region named B [9]. Further, three point mutations distinguish 
type III mRNA from group II wt mRNAs. At position 44 on 
type III mRNA, a T replaces the C (position +9 on truncated 
mRNAs), and codon 8 GCC is replaced by CGC in type III 
mRNA. 
The sequence of the type III GGT mRNA presents only 
one possible open reading frame (ORF) beginning with an 
ATG at position 36 and continuing to position 812. It encodes 
a 260 amino acid polypeptide which sequence reveals: (i) 7 
point mutations at positions 8 (Ala--* Arg), 34 (Asp ~ Val), 75 
(Asn ~ Asp), 84 (Ser ~ Asn), 248 (Glu ~ Val), 251 
(Gly ~ Thr) and 252 (Tyr--* Glu); (ii) a 27 amino acid inser- 
tion due to the unspliced intron; (iii) a later stop codon due to 
a point mutation that suppresses the first TGA and produces 
an addition of 7 amino acids (Fig. 3). Because of the presence 
of the unspliced intron and point mutations, this polypeptide 
has about 80% homology with the amino acid sequence de- 
duced from wild-type truncated mRNA peptide [9]. 
3.3. GGT type I and type III mRNAs expression in 
haematopoietic cells 
The detection of the type I and type III GGT specific 
mRNAs in patients suffering from leukemia was achieved 
using RT-PCR with two set primers Amp 1-Amp 2 for type 
I and Amp 1-Amp 5 for type III. 
As shown in Table 1, GGT type I transcripts were observed 
in samples of healthy subjects and patients as well as in the 
cell lines HL60, U937 and K562. In contrast, the product 
corresponding to type III mRNA was found in neither lym- 
phocytes of healthy subjects nor in the haematopoietic cell 
lines. However, the product corresponding to this type of 
mRNA was found in 48% of the ALL subjects. 
4. Discussion 
Previous investigations have established the presence of at 
least seven genes for human GGT [3] while in rat and mouse 
the enzyme is encoded by a single gene [19]. From the seven 
genes, at least five are actively transcribed in various tissues 
but only the structures of two distinct mRNAs have been 
described. 
The GGT cDNA we cloned corresponds to the gene 1 tran- 
script previously described [3]. In general, it presents the same 
open reading frame (ORF) as the lung truncated mRNAs but 
differs by the addition of 81 bp due to the unspliced intron 
and several point mutations as described in Section 3. 
The sequence of gene 1 upstream from the last cDNA base 
is identical to the 5'UTR of the truncated lung GGT mRNAs 
and to an intron in the GGT gene 6 (not shown). As all these 
mRNAs do not exceed 1.2 kb, we conclude that they start 
within this intron whether or not they are encoded by trun- 
cated genes. It is not clear if they are transcribed by a specific 
promoter or whether they represent specifically processed 
transcripts of the entire GGT precursor mRNA. 
The amino-terminus of the precursor part of the putative 
polypeptide does not contain any particular address equence 
nor does it have any structural homology with the amino- 
terminal anchoring peptide of the whole GGT molecule. As 
the cleavage of the GGT precursor takes place either in the 
endoplasmic reticulum or in the plasma membrane [20], it is 
possible that the truncated peptide is not cleaved. 
The small subunit of the GGT contains the 5,-glutamyl do- 
nor site but both subunits are required for activity [21]. Only 
262 
Table 1 
Type I and type III GGT mRNA expression in hematopoietic cells 
No. Lymphocytes Pathology State of treatment 
Type I a Type liP' 
P1 + - ALL diagnosis c 
P2 + ALL bone narrow relapse 
P3 + - ALL diagnosis ~ 
P4 + ALL bone narrow relapse 
P5 + ALL diagnosis ~ 
P6 + + ALL diagnosis ': 
P7 + + ALL bone narrow relapse 
P8 + + ALL diagnosis c 
P9 + + ALL diagnosis ~ 
P10 ND - ALL remission 
P11 + - ALL bone narrow relapse 
P12 + ALL diagnosis': 
PI 3 + + ALL diagnosis c 
PI4 - + ALL diagnosis ~ 
PI5 - ALL diagnosis '~
P16 + ALL diagnosis ' 
P17 + + ALL bone narrow relapse 
Tl + 
T2 + 
T3 + 
T4 + 
T5 + 
T6 + 
T7 + 
T8 + 
T9 + 
T10 + 
Cell line 
HL60 + 
K562 + 
U937 + 
+ and represent, respectively, the presence or absence of PCR prod- 
ucts. 
PI-P17 are RNAs prepared from ALL patient hematopoietic cells; 
T1-T10 are RNAs prepared from blood cells of healthy donors. 
~Type I represents Amp l-Amp 2 PCR reactions. 
bType III represents Amp l-Amp 5 PCR reactions. 
°Blood samples were collected before any tratment during the first 
hospitalization of the subject. 
very early investigations have postulated that the small sub- 
unit alone could have a proteolytic activity [2]. Thus, it seems 
that the translation products of type III mRNA and of the 
other truncated mRNAs  do not exhibit any GGT related 
activity. Furthermore, it is unlikely that these polypeptides 
could combine with the GGT heavy subunit to form an active 
enzyme. 
Truncated GGT mRNAs have been identified in lung and 
the type III mRNA in placenta and sigmoid tissues. Surpris- 
ingly, we found this type of mRNA in about 50% of samples 
from ALL patients uggesting that it could represent a specific 
marker for this disease. As GGT genes are located near the 
bcr genes, type III mRNA pathology-specific transcription 
could be the consequence of the chromosomal breaks and 
rearrangements affecting this region, notably in the case of 
H. Leh et al./FEBS Letters 394 (1996) 258-262 
the ALL-associated Philadelphia chromosome [5]. However, 
our results do not allow us to correlate the type III mRNA 
expression either with ALL  state or bcr-abl rearrangement. As
the physiological function of this mRNA is not clear, further 
studies including specific antibody detection of translation 
products are in progress. 
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